Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Effects of Semaglutide on Glycemic Control and Weight Loss in a Patient with Prader-Willi Syndrome: A Case Report

Author(s): Elena Sani*, Giuliana Da Prato, Maria Grazia Zenti, Andrea Bordugo, Maddalena Trombetta and Enzo Bonora

Volume 22, Issue 10, 2022

Published on: 30 June, 2022

Page: [1053 - 1057] Pages: 5

DOI: 10.2174/1871530322666220509225637

Price: $65

Abstract

Background: Prader-Willi syndrome is the most frequent genetic cause of obesity and is often complicated by glucose metabolism alterations. Conventional therapies prescribed for type 2 diabetes frequently failed to achieve adequate glycemic control in patients with Prader-Willi syndrome. Beneficial effects of glucagon like peptide-1 receptor agonists exenatide and liraglutide have been reported for the management of type 2 diabetes in Prader-Willi syndrome, but no data are currently available in this population on the use of semaglutide.

Case Presentation: We report for the first time the use of semaglutide 1 mg per week in a 33-yearold man with Prader-Will syndrome complicated by poorly controlled diabetes and severe obesity. After 12 months of semaglutide treatment, we observed an important reduction in glycated hemoglobin levels (11.1% to 7.2%) and body weight (99.5 kg to 94.3 kg), with a notable decrease in fat mass and insulin requirements. Interestingly, our patient had already tried liraglutide therapy in adjunction to metformin and insulin therapy, reporting no substantial efficacy.

Conclusion: The beneficial effects of semaglutide on glycemic control and weight reduction provide a promising treatment for diabetes and obesity in Prader-Willi syndrome, even where other glucagons like peptide-1 receptor agonists have failed. Further studies are required to confirm the efficacy and safety of semaglutide in patients with Prader-Willi syndrome.

Keywords: Semaglutide, Prader-Willi syndrome, diabetes mellitus, obesity, gLP-1RA, hyperphagia, weight loss, glycemical control.

« Previous Next »
Graphical Abstract

[1]
Angulo, M.A.; Butler, M.G.; Cataletto, M.E. Prader-Willi syndrome: A review of clinical, genetic, and endocrine findings. J. Endocrinol. Invest., 2015, 38(12), 1249-1263.
[http://dx.doi.org/10.1007/s40618-015-0312-9] [PMID: 26062517]
[2]
Cassidy, S.B.; Schwartz, S.; Miller, J.L.; Driscoll, D.J. Prader-Willi syndrome. Genet. Med., 2012, 14(1), 10-26.
[http://dx.doi.org/10.1038/gim.0b013e31822bead0] [PMID: 22237428]
[3]
Muscogiuri, G.; Formoso, G.; Pugliese, G.; Ruggeri, R.M.; Scarano, E.; Colao, A. Prader- Willi syndrome: An uptodate on endocrine and metabolic complications. Rev. Endocr. Metab. Disord., 2019, 20(2), 239-250.
[http://dx.doi.org/10.1007/s11154-019-09502-2] [PMID: 31065942]
[4]
Fintini, D.; Grugni, G.; Bocchini, S.; Brufani, C.; Di Candia, S.; Corrias, A.; Delvecchio, M.; Salvatoni, A.; Ragusa, L.; Greggio, N.; Franzese, A.; Scarano, E.; Trifirò, G.; Mazzanti, L.; Chiumello, G.; Cappa, M.; Crinò, A. Disorders of glucose metabolism in Prader-Willi syndrome: Results of a multicenter Italian cohort study. Nutr. Metab. Cardiovasc. Dis., 2016, 26(9), 842-847.
[http://dx.doi.org/10.1016/j.numecd.2016.05.010] [PMID: 27381990]
[5]
Crinò, A.; Grugni, G. Update on diabetes mellitus and glucose metabolism alterations in Prader-Willi syndrome. Curr. Diab. Rep., 2020, 20(2), 7.
[http://dx.doi.org/10.1007/s11892-020-1284-5] [PMID: 32030506]
[6]
Cheang, J.Y.; Moyle, P.M. Glucagon-Like Peptide-1 (GLP-1)-based therapeutics: Current status and future opportunities beyond type 2 diabetes. ChemMedChem, 2018, 13(7), 662-671.
[http://dx.doi.org/10.1002/cmdc.201700781] [PMID: 29430842]
[7]
Seetho, I.W.; Jones, G.; Thomson, G.A.; Fernando, D.J. Treating diabetes mellitus in prader-willi syndrome with exenatide. Diabetes Res. Clin. Pract., 2011, 92(1), e1-e2.
[http://dx.doi.org/10.1016/j.diabres.2010.12.009] [PMID: 21227526]
[8]
Sze, L.; Purtell, L.; Jenkins, A.; Loughnan, G.; Smith, E.; Herzog, H.; Sainsbury, A.; Steinbeck, K.; Campbell, L.V.; Viardot, A. Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome. J. Clin. Endocrinol. Metab., 2011, 96(8), E1314-E1319.
[http://dx.doi.org/10.1210/jc.2011-0038] [PMID: 21632815]
[9]
Salehi, P.; Hsu, I.; Azen, C.G.; Mittelman, S.D.; Geffner, M.E.; Jeandron, D. Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome. Pediatr. Obes., 2017, 12(3), 221-228.
[http://dx.doi.org/10.1111/ijpo.12131] [PMID: 27071367]
[10]
Cyganek, K.; Koblik, T.; Kozek, E.; Wojcik, M.; Starzyk, J.; Malecki, M.T. Liraglutide therapy in Prader-Willi syndrome. Diabet. Med., 2011, 28(6), 755-756.
[http://dx.doi.org/10.1111/j.1464-5491.2011.03280.x] [PMID: 21388446]
[11]
Senda, M.; Ogawa, S.; Nako, K.; Okamura, M.; Sakamoto, T.; Ito, S. The glucagon-like peptide-1 analog liraglutide suppresses ghrelin and controls diabetes in a patient with Prader-Willi syndrome. Endocr. J., 2012, 59(10), 889-894.
[http://dx.doi.org/10.1507/endocrj.EJ12-0074] [PMID: 22785236]
[12]
Fintini, D.; Grugni, G.; Brufani, C.; Bocchini, S.; Cappa, M.; Crinò, A. Use of GLP-1 receptor agonists in Prader-Willi Syndrome: Report of six cases. Diabetes Care, 2014, 37(4), e76-e77.
[http://dx.doi.org/10.2337/dc13-2575] [PMID: 24652737]
[13]
Kim, Y.M.; Lee, Y.J.; Kim, S.Y.; Cheon, C.K.; Lim, H.H. Successful rapid weight reduction and the use of liraglutide for morbid obesity in adolescent Prader-Willi syndrome. Ann. Pediatr. Endocrinol. Metab., 2020, 25(1), 52-56.
[http://dx.doi.org/10.6065/apem.2020.25.1.52] [PMID: 32252218]
[14]
Goldenberg, R.M.; Steen, O. Semaglutide: Review and place in therapy for adults with type 2 diabetes. Can. J. Diabetes, 2019, 43(2), 136-145.
[http://dx.doi.org/10.1016/j.jcjd.2018.05.008] [PMID: 30195966]
[15]
Wilding, J.P.H.; Batterham, R.L.; Calanna, S.; Davies, M.; Van Gaal, L.F.; Lingvay, I.; McGowan, B.M.; Rosenstock, J.; Tran, M.T.D.; Wadden, T.A.; Wharton, S.; Yokote, K.; Zeuthen, N.; Kushner, R.F. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med., 2021, 384(11), 989-1002.
[http://dx.doi.org/10.1056/NEJMoa2032183] [PMID: 33567185]
[16]
Haqq, A.M.; Muehlbauer, M.J.; Newgard, C.B.; Grambow, S.; Freemark, M. The metabolic phenotype of Prader-Willi syndrome (PWS) in childhood: Heightened insulin sensitivity relative to body mass index. J. Clin. Endocrinol. Metab., 2011, 96(1), E225-E232.
[http://dx.doi.org/10.1210/jc.2010-1733] [PMID: 20962018]
[17]
Lacroix, D.; Moutel, S.; Coupaye, M.; Huvenne, H.; Faucher, P.; Pelloux, V.; Rouault, C.; Bastard, J.P.; Cagnard, N.; Dubern, B.; Clément, K.; Poitou, C. Metabolic and adipose tissue signatures in adults with Prader-Willi syndrome: A model of extreme adiposity. J. Clin. Endocrinol. Metab., 2015, 100(3), 850-859.
[http://dx.doi.org/10.1210/jc.2014-3127] [PMID: 25478934]
[18]
Goldstone, A.P.; Thomas, E.L.; Brynes, A.E.; Bell, J.D.; Frost, G.; Saeed, N.; Hajnal, J.V.; Howard, J.K.; Holland, A.; Bloom, S.R. Visceral adipose tissue and metabolic complications of obesity are reduced in Prader-Willi syndrome female adults: Evidence for novel influences on body fat distribution. J. Clin. Endocrinol. Metab., 2001, 86(9), 4330-4338.
[http://dx.doi.org/10.1210/jcem.86.9.7814] [PMID: 11549670]
[19]
Miller, J.L.; Linville, T.D.; Dykens, E.M. Effects of metformin in children and adolescents with Prader-Willi syndrome and early-onset morbid obesity: A pilot study. J. Pediatr. Endocrinol. Metab., 2014, 27(1-2), 23-29.
[http://dx.doi.org/10.1515/jpem-2013-0116] [PMID: 23893676]
[20]
Bekx, M.T.; Carrel, A.L.; Shriver, T.C.; Li, Z.; Allen, D.B. Decreased energy expenditure is caused by abnormal body composition in infants with Prader-Willi Syndrome. J. Pediatr., 2003, 143(3), 372-376.
[http://dx.doi.org/10.1067/S0022-3476(03)00386-X] [PMID: 14517523]
[21]
Blundell, J.; Finlayson, G.; Axelsen, M.; Flint, A.; Gibbons, C.; Kvist, T.; Hjerpsted, J.B. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes. Metab., 2017, 19(9), 1242-1251.
[http://dx.doi.org/10.1111/dom.12932] [PMID: 28266779]
[22]
O’Neil, P.M.; Birkenfeld, A.L.; McGowan, B.; Mosenzon, O.; Pedersen, S.D.; Wharton, S.; Carson, C.G.; Jepsen, C.H.; Kabisch, M.; Wilding, J.P.H. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: A randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet, 2018, 392(10148), 637-649.
[http://dx.doi.org/10.1016/S0140-6736(18)31773-2] [PMID: 30122305]
[23]
Muscogiuri, G.; Barrea, L.; Faggiano, F.; Maiorino, M.I.; Parrillo, M.; Pugliese, G.; Ruggeri, R.M.; Scarano, E.; Savastano, S.; Colao, A. Obesity in Prader-Willi syndrome: Physiopathological mechanisms, nutritional and pharmacological approaches. J. Endocrinol. Invest., 2021, 44(10), 2057-2070.
[http://dx.doi.org/10.1007/s40618-021-01574-9] [PMID: 33891302]
[24]
Capehorn, M.S.; Catarig, A.M.; Furberg, J.K.; Janez, A.; Price, H.C.; Tadayon, S.; Vergès, B.; Marre, M. Efficacy and safety of once-weekly semaglutide 1.0mg vs. once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab., 2020, 46(2), 100-109.
[http://dx.doi.org/10.1016/j.diabet.2019.101117] [PMID: 31539622]
[25]
Ahmann, A.J.; Capehorn, M.; Charpentier, G.; Dotta, F.; Henkel, E.; Lingvay, I.; Holst, A.G.; Annett, M.P.; Aroda, V.R. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 Diabetes (SUSTAIN 3): A 56-week, open-label, randomized clinical trial. Diabetes Care, 2018, 41(2), 258-266.
[http://dx.doi.org/10.2337/dc17-0417] [PMID: 29246950]
[26]
Pratley, R.E.; Aroda, V.R.; Lingvay, I.; Lüdemann, J.; Andreassen, C.; Navarria, A.; Viljoen, A. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): A randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol., 2018, 6(4), 275-286.
[http://dx.doi.org/10.1016/S2213-8587(18)30024-X] [PMID: 29397376]
[27]
Lau, J.; Bloch, P.; Schäffer, L.; Pettersson, I.; Spetzler, J.; Kofoed, J.; Madsen, K.; Knudsen, L.B.; McGuire, J.; Steensgaard, D.B.; Strauss, H.M.; Gram, D.X.; Knudsen, S.M.; Nielsen, F.S.; Thygesen, P.; Reedtz-Runge, S.; Kruse, T. Discovery of the once-weekly Glucagon-Like Peptide-1 (GLP-1) analogue semaglutide. J. Med. Chem., 2015, 58(18), 7370-7380.
[http://dx.doi.org/10.1021/acs.jmedchem.5b00726] [PMID: 26308095]
[28]
Brunton, S.A. An overview of the burden of illness and the role of once-weekly glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes. J. Fam. Pract., 2018, 67(6)(Suppl.), S3-S7.
[PMID: 29912995]

Rights & Permissions Print Cite
Article Metrics
29
1
© 2024 Bentham Science Publishers | Privacy Policy